Daratumumab In Transplant Regimens For Myeloma?

When autologous transplantation is chosen in patients newly diagnosed with multiple myeloma, the standard pretransplant induction and posttransplant consolidation therapy is the triple combination of lenalidomide, bortezomib, and dexamethasone (RVd). In this issue of Blood, however, Voorhees et al show that the addition of daratumumab to this regimen increased rates of stringent complete response (CR) and minimal residual disease (MRD) negativity at the end of consolidation. Because the safety profile of this new combination was acceptable, the authors state that this combination may be a potential new standard for transplant-eligible myeloma patients.(1)